1/8
07:01 am
drts
Wall Street Breakfast Podcast: Selloff To Surge In Defense [Seeking Alpha]
Medium
Report
Wall Street Breakfast Podcast: Selloff To Surge In Defense [Seeking Alpha]
1/6
10:56 am
drts
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study [Yahoo! Finance]
Medium
Report
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study [Yahoo! Finance]
1/6
09:00 am
drts
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
High
Report
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
1/6
01:48 am
drts
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation [Globe and Mail, The (Toronto, Canada)]
1/5
09:15 am
drts
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) [Yahoo! Finance]
Low
Report
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) [Yahoo! Finance]
1/5
09:00 am
drts
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Medium
Report
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
12/18
09:00 am
drts
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
Medium
Report
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
12/10
02:28 pm
drts
Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $7.00. They now have a "buy" rating on the stock.
12/10
01:04 pm
drts
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/9
09:00 am
drts
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
Medium
Report
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
12/4
09:00 am
drts
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
Low
Report
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
12/2
09:00 am
drts
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
Medium
Report
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
12/1
09:13 am
drts
Alpha Tau to Participate in December Investor Conferences [Yahoo! Finance]
Medium
Report
Alpha Tau to Participate in December Investor Conferences [Yahoo! Finance]
12/1
09:00 am
drts
Alpha Tau to Participate in December Investor Conferences
Medium
Report
Alpha Tau to Participate in December Investor Conferences
11/24
08:06 am
drts
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
11/20
04:20 pm
drts
Alpha Tau Medical GAAP EPS of -$0.39 [Seeking Alpha]
High
Report
Alpha Tau Medical GAAP EPS of -$0.39 [Seeking Alpha]
11/20
04:05 pm
drts
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
11/11
08:30 am
drts
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
Medium
Report
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
11/1
01:05 am
drts
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at
Wall Street
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at
Wall Street
10/22
10:49 am
drts
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.